

MARKED-UP SPECIFICATION SHOWING CHANGES MADE

**CRYSTALLINE CITALOPRAM DIOL INTERMEDIATE ALKALIBASE**



This is a U.S. national stage application ~~nationalization~~ of PCT/CN2004/001418 filed December 6, 2004 and published in Chinese.

5

**Technological domain Field of The Invention**


The present invention relates to the diol intermediate of citalopram useful for treatment of depression, ~~that is to say,~~ more specifically, the pure crystal ~~alkali~~base of 3-hydroxymethyl-4-[1-(4-fluorophenyl)-1-hydroxyl-4-(dimethylamino)] butylbenzonitrile and the method of purification thereof, and relates to the method of preparing citalopram purified salts from the obtained crystal ~~alkali~~base. The present invention also relates to the optical resolution method of the described crystal ~~alkali~~base, the method to prepare S-citalopram purified salts, the method to prepare citalopram and its purified salts, S-citalopram and its purified salts, as well as pharmaceutical formulation obtained thereof.

15 ~~thereof obtained.~~

**Background of the invention The Invention**

Citalopram is a well-known antidepressant drug. It is a selective, centrally acting serotonin (5-hydroxytryptamine) reuptake inhibitor, accordingly having antidepressant activities. The antidepressant activity of the compound has been reported in several publications, e.g. J. Hyttel, Prog. Neuro-Psychopharmacol. & Biol. Psychiat.) 1982, 6, 277-295 and A. Gravem, Acta Psychiatr. Scand.) 1987, 75, 478-486. These publications also disclosed the effects of the compound in the treatment of dementia and cerebrovascular disorders. The structure of citalopram is as follows:

20



## II

The synthesis of citalopram was first disclosed in US4136193 in 1977 and in DE2657271 in 1979, ~~they~~ 1979. ~~They~~ both described the preparation of citalopram. As an antidepressant drug, citalopram has been on market in more than sixty countries. There are many patent publications concerning the preparation of citalopram, for example:

1. The starting material 5-cyanophthalide is subjected to: (1) two successive Grignard reactions with 4-bromofluorophenyl and N,N-dimethylaminopropyl chloride, respectively; (2) hydrolysis of the product in dilute acid to give obtain citalopram diol intermediate; (3) ring closure with acid; (4) purification and salt formation with bromic acid to give obtain citalopram (US4560884) .

2. The starting material 5-aminophthalide is subjected to two successive Grignard reactions, hydrolysis, ring closure by dehydration, diazotization and salt formation with bromic acid to give obtain citalopram (WO 98/19512) .



3. The starting material 5-cyanophthalide is subjected to Grignard reaction with 4-bromofluorophenyl, hydrolysis, reduction by sodium borohydride, ring closure and a second Grignard reaction with N,N-dimethylaminopropyl chloride to give obtain citalopram. (WO 9819511) .

4. The starting material 5-cyanophthalide is subjected to Grignard reaction with 4-bromofluorophenyl, hydrolysis, esterification, a second Grignard reaction with N,N-dimethylaminopropyl chloride and hydrolysis with acid to give obtain citalopram diol intermediate. The intermediate is then subjected to ring closure with acid, purification, and salt formation with bromic acid to give obtain citalopram (WO 0012044) .

There are many other methods concerning the preparation of ~~citalopram, not citalopram~~. No matter which is adopted, ~~a lot of many~~ purification processes are required in order to obtain relatively purer product. Though ~~a lot of many~~ purification processes which may result in the loss of citalopram are employed, the impurities, especially those having ~~identical~~ similar structures with the product, are hard to eliminate.

It is well known~~to all~~ that some of the impurities are from the early starting materials of citalopram or S-citalopram. For example, ~~according to the~~depending on different starting materials, 5-cyanophthalide can be ~~conversed~~converted from 5-bromophthalide, 5-chlorophthalide, 5-aminophthalide, 5-amidophthalide, 5-esterphthalide, 5-methylacylphthalide, 5-oxazolinyphthalide, 5-thiazolinyphthalide, 5-carboxylphthalide or phthalide whose 5-substituted group is  $-O-SO_2-(CF_2)_n-CF_3$ . Due to the ~~halfway~~incomplete conversion of the early starting materials, those materials as well as the impurities which resulted from the conversion process have ~~identical~~similar structures with 5-cyanophthalide, and will more or less exist among 5-cyanophthalide. They will be further ~~converse~~converted into other impurities, which have ~~identical~~similar structures with citalopram diol intermediate, in the following process of preparing citalopram diol intermediate. The impurities exist among the early starting materials and the intermediates and have ~~identical~~similar structures with those materials or intermediates in different stages. They will be further ~~converse~~converted into the impurities which have ~~identical~~similar structures with the ultimate product during the synthesis process of citalopram or S- citalopram.

One or several previously mentioned impurities, other impurities resulted from the conversion and disposal processes may exist among the citalopram diol intermediate. For instance, there may exit impurities like the following III and/or IV.



In Formula III, Z is halogen;  $-O-SO_2-(CF_2)_n-CF_3$ , wherein n is 0-8;  $-CHO$ ;  $-NHR^1$ ;  $-COOR^2$ ;  $-CONR^2R^3$ ; wherein  $R^2$  and  $R^3$  is hydrogen, alkyl, any substitutional aryl or arylalkyl,  $R^1$  is hydrogen or alkylcarbonyl.

Although there are several disclosed methods such as those in GB2356199、WO03/072565

for purifying citalopram crude product, which can effectively eliminate one or several of the impurities. In GB2356199, a short vacuum distillation is employed, which requires expensive equipments and complex operations; in operations. In WO03/072565, complex operations like several salt formation processes and several careful pH adjustments are ~~required, these~~ required.

5 These long purifying processes result in loss of the product while achieving limited results.

It is well-known ~~to all~~ that citalopram has two enantiomers: S-citalopram and R-citalopram. It is S-citalopram that has the antidepressant activities; R-citalopram hardly has such activities. ~~At present,~~ Presently, S-citalopram salt has been on market. When preparing for S-citalopram, usually chiral organic acid is reacted with the amino group of citalopram diol ~~intermediate,~~ intermediate.

10 Then the enantiomers are ~~then~~ resolved according to their solubility, or reacted with the 3-substituted hydroxymethyl of citalopram diol intermediate free ~~alkali~~ base to form diastereomeric esters and then resolved through crystallization or column chromatography. Among those resolution methods, the most extensively used one is that citalopram diol intermediate is subjected to salt formation with a chiral organic acid and then the obtained enantiomers are resolved through  
15 crystallization. The method is convenient but requires a ~~lot~~ large amount of chiral organic acid. In addition, WO 03/000672 disclosed a method of resolution non-racemic mixture of S-citalopram and R-citalopram through deposit crystallization. Through separating the deposit and the mother liquor, the enantiomer with a relatively high content was collected in the mother liquor and resolved. The obtained R-citalopram ~~can't~~ cannot be used at present. During the stage of resolving citalopram diol  
20 intermediate, the obtained R-citalopram diol intermediate can be effectively ~~used, for~~ used. For instance, WO 03/000672 disclosed a method of ~~converting~~ converting it into the mixture of R-citalopram and ~~S-citalopram, the~~ S-citalopram. The mixture was further separated to ~~give~~ obtain the racemates of citalopram diol intermediate or mixture of near ~~racemates;~~ racemates. It can also be used to form salt with a chiral organic acid and then resolved or used to prepare citalopram  
25 through ring closure.

In GB2357762, citalopram ~~alkali~~ base was purified through crystallization of racemic citalopram free ~~alkali, the~~ base. The purification of S-citalopram ~~is~~ was not yet mentioned, nor ~~is~~ was the crystallization of S-citalopram ~~alkali.~~ base.

~~So, Therefore,~~ a more effective and economical purification method is ~~required~~needed for the industrial production of citalopram. ~~And for~~For the preparation of S-citalopram in particular, a more effective and simpler method is ~~required~~needed.

**The contents of invention****Summary of The Invention**

5 ~~We have~~It has been discovered that quite pure citalopram diol intermediate free ~~alkali~~base can be obtained. ~~We have also surprisingly~~Surprisingly, it has been discovered that the described ~~alkali~~base can be effectively purified through ~~crystallization,~~the crystallization. The method is easy to ~~manipulate~~implement and high yield can be achieved. ~~We have also~~In addition, it has been discovered that using the described ~~alkali~~base as starting material, pure citalopram or S-citalopram  
10 can be effectively prepared. The present invention provides an effective and simple method for purifying citalopram diol intermediate, through the crystallization of the described ~~alkali,~~base, quite pure citalopram diol intermediate can be obtained. Using the purified citalopram diol intermediate as starting material, quite pure citalopram and its acid addition salts can be prepared effectively and simply.


15 ~~What's more important is that: we have~~More importantly, it has been discovered that the pure citalopram diol intermediate obtained through crystallization of the described ~~alkali~~base is able to be resolved to prepare pure S-citalopram diol intermediate effectively and simply. The obtained S-citalopram diol intermediate is further ~~converted~~converted into S-citalopram and its acid addition salts effectively and simply. The present invention provides a novel method for the commercial  
20 production of pure S-citalopram, reducing the cockamamie and expensive purification processes.

In another aspect, the present invention also provides a method of resolution the mixture of S-citalopram and R-citalopram that is not entirely racemic. Through the direct crystallization of the crystal ~~alkali,~~base, the mixture is effectively resolved in the form of free ~~alkali,~~base. The method can be alternated or combined with the resolution method which uses a chiral organic acid as  
25 resolving agent, saving the required amount of resolving agent and improving the yield.


Citalopram diol intermediate oil substance and citalopram diol intermediate raw mixture or raw salt can be prepared according to the method described in USP 4560884: the starting material 5-cyanophthalide is subjected to two successive Grignard reactions with 4-fluorophenyl magnesium

halide (e.g. 4-fluorophenyl magnesium bromide) and N,N-dimethylaminopropyl magnesium halide (e.g. N,N-dimethylaminopropyl magnesium chloride); or prepared according to the method described in WO 0012044: the starting material 5-cyanophthalide is subjected to Grignard reaction with 4-fluorophenyl magnesium halide (eg.4-bromofluorophenyl), hydrolysis, esterification, a second Grignard reaction with N,N-dimethylaminopropyl magnesium halide (e.g. N,N-dimethylaminopropyl magnesium ~~chloride~~). ~~Wherein, chloride~~, wherein, the chemical nomination for 5-cyanophthalide is 5-cyano-2-benz[c]furanone, which can be ~~converted~~converted from 5-bromophthalide, 5-chlorophthalide, 5-aminophthalide, 5-amidophthalide, 5-esterphthalide, 5-methylacylphthalide, 5-oxazolinyphthalide, 5-thiazolinyphthalide, 5-carboxylphthalide or phthalide whose 5-substituted group is -O-SO<sub>2</sub>-(CF<sub>2</sub>)<sub>n</sub>-CF<sub>3</sub>. They can also be bought from companies like H • Lundbeck, a Danish company which sells the commercial product of citalopram diol intermediate mixture.

~~We have~~It has been discovered that citalopram diol intermediate free ~~alkali, that is to say, base,~~ which is, the crystal alkali~~base~~ of 3-hydroxymethyl-4-[1-(4-fluorophenyl)-1-hydroxyl-4-(dimethylamino)] butylbenzonitrile, is a tintless or white crystal with the following chemical structure:



I



II (mixture of S and R)

20



~~We have also~~It has also been discovered a method of preparing crystal product of citalopram diol intermediate and its ~~salt, through salt.~~ Through this method, the product obtained is pure and with a good crystal form and the yield is high. Citalopram diol intermediate free ~~alkali~~base is freed and precipitated in the form of crystal. The free ~~alkali~~base is subjected to crystallization one or more

times to ~~give~~obtain the crystal, the crystal is further subjected to ring closure by dehydration to ~~give~~obtain citalopram. The obtained citalopram is further ~~converted~~conversed into citalopram salt, ~~the salt~~. The obtained salt is subjected to crystallization one or more times to give citalopram salt. The preferred citalopram salt is hydrobromic salt or hydrochloric salt.

5 The present invention relates to a method of preparing S- citalopram and its salts. Citalopram diol intermediate ~~alkali~~base is freed and precipitated in the form of crystal. Purified citalopram diol intermediate ~~alkali~~base is obtained through crystallization one or more times and then subjected to resolution and ring closure by dehydration to ~~give~~obtain S- citalopram. The obtained S-citalopram is further ~~converted~~conversed into S-citalopram salts, the obtained salts are  
10 subjected to crystallization one or more times to ~~give~~obtain S-citalopram salts.

The citalopram diol intermediate ~~alkali~~base and its salt prepared through the method provided by the present invention is suitable for resolution. Before resolution, the preferred chemical purity of citalopram diol intermediate ~~alkali~~base is over 99.8%, while after resolution, the purity of the enantiomer is over 99.9%.

15 The present invention relates to a method of preparing citalopram, S- citalopram and its salts, which is characterized by: through crystallization of the described ~~alkali~~base, citalopram diol intermediate free ~~alkali~~base was purified. Through crystallization, citalopram diol intermediate was freed from its crude salt or crude mixture so that one or more impurities with the following III and/or IV structures was eliminated, so citalopram diol intermediate free ~~alkali~~base with a chemical  
20 purity of over 99.8%(w/w) was easily obtained.




In Formula III, Z is halogen;  $-O-SO_2-(CF_2)_n-CF_3$ , wherein n is 0-8;  $-CHO$ ;  $-NHR^1$ ;  $-COOR^2$ ;

-CONR<sup>2</sup>R<sup>3</sup>; wherein R<sup>2</sup> and R<sup>3</sup> is hydrogen, alkyl, any substitution aryl or arylalkyl, R<sup>1</sup> is hydrogen or alkylcarbonyl. Pure citalopram or S-citalopram and its salts can effectively be prepared from the obtained pure citalopram diol intermediate.

The present invention overcomes the limitations of the existing technologies, putting forward a novel method of preparing high pure citalopram diol intermediate free ~~alkali~~base crystal through crystallization. Through ring closure by dehydration of the crystal ~~alkali~~base, quite pure citalopram is ~~obtained; the~~obtained. The obtained citalopram is then subjected to ordinary purifying processes, such as salt formation with hydrobromic acid; the obtained salt is then crystallized and recrystallized to ~~give~~obtain pure citalopram and its salts. ~~Or~~Alternatively, the obtained pure citalopram diol intermediate free ~~alkali~~base crystal can be resolved to produce pure enantiomer. Through appropriate ring closure of the enantiomer, pure S-citalopram is obtained. Then salt is produced from the obtained ~~alkali~~base, through the ordinary purifying processes of the salt, such as crystallization or recrystallization, pure citalopram or S-citalopram and its salts can be obtained effectively.

In another aspect, ~~we have~~it has been discovered that citalopram diol intermediate free ~~alkali~~base can be resolved through crystallization. Through the crystallization of the racemic citalopram diol intermediate free ~~alkali~~base crystal, a mixture of S- and R-citalopram diol intermediate with more than 50% of one of the enantiomers is resolved. The obtained pure S-enantiomer is further subjected to ring closure to ~~give~~obtain pure S-citalopram. (Formula II<sup>1</sup>)



II<sup>1</sup> (S- citalopram)

The present invention relates to a method of preparing R-citalopram free ~~alkali~~base or S-citalopram free ~~alkali~~base and its acid addition salts. Through the crystallization of the described



MARKED-UP SPECIFICATION SHOWING CHANGES MADE

~~alkali,base~~, a mixture of S- and R- citalopram diol intermediate with more than 50% of one of the enantiomers is resolved. The method includes the following steps;

1) Citalopram diol intermediate is precipitated or crystallized from the solution or the solventless oil substance in the form of free ~~alkali,base~~;

5 2) The precipitate or crystal is separated from the mother liquor or the oil substance;

The remained citalopram diol intermediate optical enantiomers in the mother liquor or the oil citalopram diol intermediate optical enantiomers are resolved and their optical rotation are improved. Then S- or R-citalopram diol intermediate is separated from the mother liquor.

10 ~~Or Alternatively,~~ the obtained solventless oil ~~alkali-isbase~~ ~~econverted~~is converted into S- or R-citalopram through ring closure, S- or R-citalopram is further ~~econverted~~converted into its acid addition salts. Wherein, S-citalopram diol intermediate is ~~econverted~~converted into S- citalopram through proper ring closure reaction, R-citalopram diol intermediate is ~~econverted~~converted into the mixture of S-citalopram and R-citalopram through proper ring closure reaction.

15 The described proper ring closure reaction by dehydration for conversing S- citalopram diol intermediate into S- citalopram can be the method disclosed in USP4945590: S-citalopram diol intermediate (Formula I ) is subjected to ring closure via a labile ester in the presence of a ~~alkali,base~~. The described proper ring closure reaction by dehydration for conversing R-citalopram diol intermediate into S-citalopram or the mixture of S-citalopram and R-citalopram can be the method disclosed in USP4136193 or WO 03/000672 where sulfuric acid or phosphoric acid with a  
20 certain concentration is used as dehydrating agent. The described proper ring closure reaction by dehydration for ~~econversing~~converting citalopram diol intermediate into citalopram can also be the method disclosed in USP4136193 where sulfuric acid or phosphoric acid with a certain concentration is used as dehydrating agent. These are the commonly used proper methods in the preparation of citalopram in this particular domain.

25 More specifically, the method provided by the present invention of preparing R- citalopram free ~~alkali,base~~ or S- citalopram free ~~alkali,base~~ and its acid addition salts includes the following steps:

1) The citalopram diol intermediate among the mixture of S- and R- citalopram diol

intermediate is precipitated from the solution or directly crystallized from the oil mixture in the form of free ~~alkali~~base;

2) The precipitate or crystal is separated from the mother liquor or the oil, and then

3) After separation, the mother liquor or the oil is further subjected to precipitation or crystallization. The S- and R-citalopram diol intermediate separated from the mother liquor or the oil is further subjected to ring closure to ~~give~~obtain S- and R- citalopram, or the mixture of S- and R-citalopram. The S-citalopram diol intermediate is subjected to ring closure to ~~give~~obtain S-citalopram, and S- citalopram can further be ~~converted~~converted into its corresponding acid addition salts.

10 In yet another aspect, the present invention relates a method of preparing R-citalopram free ~~alkali~~base or S-citalopram free ~~alkali~~base and its acid addition salts. Through the resolution of a mixture of S- and R-citalopram diol intermediate with more than 50% of one of the enantiomers, racemic citalopram diol intermediate salt and R- or S-citalopram diol intermediate salt are obtained. The method includes the following steps:

15 1) Citalopram diol intermediate is precipitated or crystallized from the solution in the form of salt;

2) The precipitate or crystal is separated from the solution;

3) The remained citalopram diol intermediate salt optical enantiomers in the mother liquor are purified through resolution, and their optical rotation are improved. Then S-or R-citalopram diol intermediate is separated from the mother liquor and ~~converted~~converted into S-or R-citalopram through ring closure, and finally ~~converted~~converted into its corresponding acid addition salts. Wherein, S-citalopram diol intermediate is ~~converted~~converted into S-citalopram through proper ring closure reaction, R-citalopram diol intermediate is ~~converted~~converted into the mixture of S-citalopram and R-citalopram through proper ring closure reaction.

25 Specifically, the method provided by the present invention of preparing R-citalopram free ~~alkali~~base or S-citalopram free ~~alkali~~base and its acid addition salts is characterized by:

1) The citalopram diol intermediate among the mixture of S- and R- citalopram diol intermediate salt mixture is precipitated or crystallized from the solution in the form of salt;

2) The precipitate or crystal is separated from the mother liquor , and then

3) After separation, the mother liquor is further subjected to precipitation or crystallization. Then S- and R- citalopram diol intermediate salt is separated from the mother liquor and set free as ~~alkali~~. ~~The alkali~~base. The base is further subjected to ring closure to ~~give~~obtain S- and R- citalopram, or the mixture of S- and R-citalopram. The S-citalopram diol intermediate is subjected to ring closure to ~~give~~obtain S-citalopram, and S-citalopram can further be ~~converted~~converted into its corresponding acid addition salts.

In the present invention, through the crystallization of the described ~~alkali~~base, a mixture of S- and R- citalopram diol intermediate with more than 50% of one of the enantiomers is directly resolved. The present resolution method can be used in combination with the method disclosed in USP4943590, so the resolving agent can be saved and resolution rate can be improved.

Resolution can be carried out by dissolving the racemic citalopram diol intermediate in proper solvent.

~~We have also~~In addition, it has been discovered that through the crystallization of the described ~~alkali~~base, S-citalopram diol intermediate mixture which contains a small amount of R-citalopram diol intermediate or R-citalopram diol intermediate mixture which contains a small amount of S-citalopram diol intermediate can be purified. The optical purity of the purified product is over ~~95%, the~~95%. The preferred purity is over ~~98.5%, the~~98.5%. The more preferred purity is over 99.0%.

Specifically, through the crystallization of the described ~~alkali~~base, S-citalopram diol intermediate mixture which contains a small amount of R-citalopram diol intermediate or R-citalopram diol intermediate mixture which contains a small amount of S-citalopram diol intermediate can be purified. If citalopram diol intermediate which needs to be purified is in the form of salt, it is first set free as ~~alkali~~base and then dissolved in the solvent. Then crystallization is carried out by adding citalopram diol intermediate crystal as crystal seed and the precipitate is separated from the mother ~~liquor~~soliquor. Thus the optical purity of citalopram diol intermediate enantiomer is improved. The purified enantiomer ~~alkali~~base is obtained after the solvent is ~~evaporated~~. ~~Wherein, evaporated, wherein,~~ the ratio of S- and R-enantiomer in the precipitate is

between 0.5 and 1.5, the preferred ratio is between 0.8 and 1.2, the most preferred ratio is 1.0, namely racemic crystal ~~alkali-~~base.

In another aspect, the present invention provides a method of preparing citalopram or S-citalopram drug preparations through crystallization of the described ~~alkali-~~base. ~~Wherein, base, wherein,~~  
 5 the preferred citalopram salt is hydro bromide salt, the preferred S-citalopram salt is oxalate salt. The preferred described preparations are for oral use.

The crystallization of the described ~~alkali-~~base is effective in purifying citalopram diol intermediate free ~~alkali-~~base. In one preferred implementation project of the present invention, citalopram diol intermediate free ~~alkali-~~base prepared according to the method described in  
 10 USP4136193 was directly dissolved in the solvent, and citalopram diol intermediate free ~~alkali-~~base crystal with a purity of over 99.9%(w/w) was obtained. The obtained crystal was dissolved in inert organic solvent and subjected to ring closure in the presence of ordinary dehydrating agent such as sulfuric acid or phosphoric acid with a certain concentration to ~~give~~obtain pure citalopram free ~~alkali-~~base. And through salt formation and recrystallization of the obtained free ~~alkali-~~base,  
 15 citalopram salt with a purity of over 99.9%(w/w) was obtained.

In another preferred implementation project of the present invention, the hydrochloric acid salt of citalopram diol intermediate, which had a highest purity of 94.6%(w/w) and contained 3%(w/w) of the previously described impurity of Formula III (wherein, Z is Br), was disposed with activated carbon and recrystallized once. After that, the impurity constituted 2.9%(w/w)  
 20 (wherein, Z is Br). Then after crystallization, the obtained crystal was suspended in isopropyl ether and disposed with NaOH solution; the organic phase was dried under vacuum and part of the isopropyl ether was recovered; the residue, in which there still remained some isopropyl ether, was crystallized by adding n-heptane into it ~~;~~ ~~theit~~. The obtained crystal was recrystallized in 70% ethanol solution and citalopram diol intermediate free ~~alkali-~~base crystal with a purity of over  
 25 99.9%(w/w) was ~~obtained;~~ thisobtained. The intermediate was dissolved in inert organic solvent and subjected to ring closure in the presence of 85% H<sub>3</sub>PO<sub>4</sub> as dehydrating agent to ~~give~~obtain citalopram free ~~alkali-~~base; ~~through~~base. Through salt formation and recrystallization of the obtained citalopram free ~~alkali-~~base, citalopram salt with a purity of over 99.9%(w/w) was obtained.

Preparing citalopram through the present invention, not only the quality of the product is improved simply and effectively, but also the yield of is improved significantly, and the production cost of the medicinal material is also reduced.

The purity of citalopram diol intermediate free ~~alkali~~base is over 99.8%(w/w), and the still preferred purity is over 99.9%(w/w). According to the present invention, citalopram diol intermediate free ~~alkali~~base is found to be a stable white or tint less, aciform and shining crystal. It is discovered that citalopram diol intermediate free ~~alkali~~base has more than one crystal form. For example, the crystal crystallized from the mixed solvent of isopropyl ether and n-heptane(v/v=1:2) has a extrapolate starting temperature of the DSC measured melting point (DSC, Onset) of 98.63°C, the peak value (DSC, Onset) of 104.18°C and the enthalpy(ΔH) of 88.13 J/g; for the XRD spectra of which—, refer to Fig. 2; ~~the~~2. The crystal crystallized from 70% ethanol solution has a extrapolate starting temperature of the DSC measured melting point (DSC, Onset) of 51.69°C, the peak value (DSC, Onset) of 59.28°C and the enthalpy(ΔH) of 38.27J/g, for the XRD spectra of which, refer to Fig.4.

The term “crude salt” and “crude mixture” refers to the salt and the mixture that contains the impurities of Formula of III and IV, the intermediates and other impurities resulted from the conversion and disposal processes, respectively.

The described crude salt can be separated from the reaction mixture and primarily purified, such as by recrystallization once, and/or disposed with active carbon or silica gel. The rude reaction mixture can primarily be purified, such as by active carbon or silica gel in the presence of acid, and the formed salt is then disposed by the methods which are already known in this domain. The described salt can be separated in the form of precipitate or kept in solvent such as water and ethanol solution.

Similarly, the crude mixture of citalopram diol intermediate can be synthesized from the described compounds according to any of the previously described methods, or primarily purified, such as by active carbon or silica gel.

Citalopram diol intermediate ~~alkali~~base can be freed from its crude salt by dissolving the crude salt in the mixture of water and organic solvent and then adding ~~alkali~~base to the mixture.

MARKED-UP SPECIFICATION SHOWING CHANGES MADE

The described organic solvent can be toluene, isopropyl ether or any other proper solvent; the described ~~alkali~~base can be any proper ~~alkali~~base, while NaOH or NH<sub>3</sub> is preferred. Similarly, citalopram diol intermediate ~~alkali~~base can be freed from its crude mixture through disposal with ~~alkali~~base when needed.

5        Before the described ~~alkali~~base is precipitated in the form of crystal, the crude salt of citalopram diol intermediate can further be purified and extracted. It can be separated as follows: the organic phase is separated and the solvent is evaporated so that the described ~~alkali~~base is obtained (the most likely form of which is oil substance), then the described ~~alkali~~base is crystallized from proper solvent. The crystallized citalopram diol intermediate free ~~alkali~~base can  
10       be recrystallized in either the same or different solvent.

      The solvent used for the crystallization of citalopram diol intermediate can be the proper single component or non-single component solvent that can dissolve citalopram diol intermediate free ~~alkali~~base. For example: alcohol such as methanol, ethanol; hydrocarbon such as hexane,  
15       heptane, cyclohexane; ether such as THF, ethyl ether, isopropyl ether; aromatic hydrocarbon; acetonitrile; acetone; ethyl acetate etc.; or the proper mixture of them. The solvent can also be the bicomponent or multicomponent mixture of water and some water-soluble solvents such as  
20       methanol, ethanol, propanol and acetone of a proper proportion. Wherein, the preferred are C<sub>1-4</sub> alcohol, the bicomponent or multicomponent mixture of C<sub>1-4</sub> alcohol and water, C<sub>>4</sub> ester, C<sub>3-8</sub> hydrocarbon and/or cycloparaffin, the mixture of C<sub>>3</sub> ester and /or cycloparaffin; the more  
25       preferred are 60%~90% methanol solution, 60%~90% ethanol solution, isopropyl ether, the mixture of isopropyl ether and hexane or heptane; the most preferred are 70% ethanol solution, the mixture of isopropyl ether and hexane (v/v=1:2), the mixture of isopropyl ether and heptane (V/V=1:2). The other proper solvents can easily be decided by a person of ordinary ~~technicians of the present domain~~skill in the art. The crystallization can be carried out either by evaporating the solvent or by  
      cooling down the solution. The crystallization temperature is different according to the solvent and the crystallization mode, which can easily be decided by ordinary technicians of the present domain. The crystallization temperature can be any proper temperature between -40 °C and the boiling point of the solvent, the preferred temperature is between -20 °C and 60 °C, the more preferred temperature

is between -5°C and room temperature. Citalopram diol intermediate can also be crystallized directly from the oil substance without adding any solvent. The conditions of crystallization can easily be decided by ordinary technicians of the present domain.

Citalopram diol intermediate free ~~alkali~~base can be resolved through crystallization.

5 Through the crystallization of the racemic citalopram diol intermediate free ~~alkali~~base crystal, a mixture of S- and R- citalopram diol intermediate with more than 50% of one of the enantiomers is resolved. The resolution can be carried out by dissolving the racemic citalopram diol intermediate in proper solvent. The solvent used is the same as that described previously, it can be methanol, ethanol, acetone, acetonitrile, ethyl ether, toluene etc. and the mixture of them: methanol and water,  
10 ethanol and water, acetone and water, acetonitrile and water etc. The resolution can also be carried out directly in the oil substance without adding any solvent.

Through ordinary purification, the purity of citalopram free ~~alkali~~base or S-citalopram free ~~alkali~~base and their acid addition salts obtained after ring closure through the present invention is over 99.5%(w/w), the preferred purity is 99.8%(w/w), and the purity of S-citalopram free ~~alkali~~base  
15 and its acid addition salts is over 97%(w/w), the preferred purity is 99%(w/w). Wherein, ordinary purification refers to: the product is disposed with active carbon and/or silica gel; the free ~~alkali~~base is purified through salt formation with acid, and/or the salt is extracted and set free with ~~alkali~~base, and/or the salt is purified through crystallization.

The racemate used for resolution can either be the obtained purified or unpurified  
20 citalopram diol intermediate oil substance or its hydrobromic salt, sulfuric salt, hydrochloric salt and oxalate salt etc., preferably the quite pure citalopram diol intermediate free ~~alkali~~base prepared through the present invention.

#### **Explanations for Figures****Brief Description of The Drawings**

Fig.1: The DSC profile of citalopram diol intermediate ~~alkali~~base crystal prepared as  
25 described in Example1, where isopropyl ether was used as solvents;

Fig.2: The XRD spectra of the prepared citalopram diol intermediate ~~alkali~~base crystal of  
Fig.1.

Fig.3: The DSC profile of citalopram diol intermediate ~~alkali~~base crystal prepared as described in Example 1, where ethanol was used as solvent;

Fig.4: The XRD spectra of the prepared citalopram diol intermediate ~~alkali~~base crystal of Fig.3.

## 5 EXAMPLES

Example 1 Preparation of high pure citalopram diol intermediate ~~alkali~~base crystal racemate

A. To 100g citalopram diol intermediate free ~~alkali~~base oil substance, 200mL isopropyl ether was added and the mixture was heated until the oil substance was dissolved entirely. Then  
10 400ml n-heptane was added ~~while~~during mixing ~~around~~ and the solution was stirred and placed aside at 5°C. After about 24 hours, a ~~lot~~large amount of crystal was crystallized. The solution was filtrated and high pure racemic citalopram diol intermediate ~~alkali~~base crystal was obtained. After dried, its melting point was measured with thermometer, which is 96--98°C. Its extrapolate starting temperature of the DSC measured melting point (DSC, Onset) is 98.63°C, the peak value (DSC, Onset) is 104.18°C, (refer to Fig.1), the enthalpy is 88.13 J/g. For the XRD Spectra, refer to Fig.2.  
15 The purity of the product was 99.9% (HPLC, area normalization method), and 95.2g product was obtained (the yield was 95.2%).

B. To 100g citalopram diol intermediate free ~~alkali~~base oil substance, 300mL ethanol was  
20 added and the mixture was heated until the oil substance was dissolved entirely. Then 140ml water was added and the solution was stirred. After the solution cooled down, crystal seed was added and the solution was placed aside at 5°C. After about 24 hours, a ~~lot~~large amount of crystal was crystallized. The solution was filtrated and 94.0g high pure racemic citalopram diol intermediate ~~alkali~~base crystal was obtained. Its melting point was measured with thermometer, which is  
25 48-52°C. Its extrapolate starting temperature of the DSC measured melting point (DSC, Onset) is 51.69°C, the peak value (DSC, Onset) is 59.28°C, (refer to Fig.3), the enthalpy is 38.27 J/g. For the XRD Spectra, refer to Fig.4. The purity of the product was 99.9% (HPLC, area normalization method), and the yield was 94.0%.



MARKED-UP SPECIFICATION SHOWING CHANGES MADE

C. To 120g citalopram diol intermediate hydrochloric salt, namely 4-dimethylamino-1-(4-bromo-2-hydroxymethylphenyl)-1-(4-fluorophenyl)-butyl-1-ol, which had a purity of 94.6% and contained 3.0%(w/w) impurities of the previous mentioned Formula III( wherein Z is Br), 400ml hot water and 40ml ethanol were ~~added;~~after added. After the salt was dissolved entirely, 12g active carbon was added and the solution was stirred for 30 min. Then the solution was filtrated and the active carbon filtrated cake was washed with 20ml hot water. The washing liquid was merged into the filtrate and the filtrate was concentrated to a residue volume of 240ml under vacuum in a hot water bath. Then the solution was placed at 5°C for about 24 hours and a ~~lot~~large amount of crystal was crystallized. The solution was filtrated to ~~give~~obtain citalopram diol intermediate hydrochloric salt crystal. The obtained crystal salt contained 2.9%(w/w) impurities of the previous mentioned Formula III (wherein Z is Br). 100g obtained crystal salt was suspended and mixed in 400ml isopropyl ether and the pH of the suspension was adjusted to above 9 with NaOH solution. The lower water phase was separated and ~~discarded,~~the discarded. The organic phase was dried, concentrated under vacuum to eliminate part of isopropyl ether. Then to the 160ml residue that still contained isopropyl ether, 400ml n-heptane was added and stirred to ~~give crystal,~~the obtain crystal. The obtained crystal was recrystallized in 70% ethanol solution and citalopram diol intermediate free ~~alkali~~base crystal with a purity of 99.9% and a yield of 91.2% was obtained.

Example 2 Resolution of S-citalopram diol intermediate

A. To 40g citalopram diol intermediate free ~~alkali~~base crystal prepared in Example 1 (purity: 99.9%, HPLC, area normalization method), 360ml isopropanol was added and the solution was heated until the crystal was dissolved entirely. 23.6g D-di-4-methylbenzyol tartaric acid was added and dissolved, the solution was placed at room temperature for 12 hours. The crystal crystallized and was filtrated, washed with small amount of isopropanol to ~~give~~obtain S-citalopram diol intermediate---D-di-4-methylbenzyol tartaric acid salt crystal. The obtained salt was then suspended and mixed in toluene, added with NaOH solution and stirred. The solution was placed aside, the organic and inorganic layer was separated. The toluene layer was heated, concentrated

MARKED-UP SPECIFICATION SHOWING CHANGES MADE

under vacuum to ~~give~~obtain 14g S-citalopram diol intermediate oil substance (yield: 70%, purity: 99.9%), in which there was 0.5% R- citalopram diol intermediate (chiral HPLC).

5 B. To 40g citalopram diol intermediate free ~~alkali~~base crystal prepared in Example 1 (purity: 99.9%, HPLC, area normalization method), 360ml isopropanol was added and the solution was heated until the crystal was dissolved entirely. 23.6g L-di-4-methylbenzyl tartaric acid was added and dissolved, the solution was placed at room temperature for 12 hours. The crystal crystallized (the mother liquor would be used in C) and was ~~filtrated, washed~~filtrated, washed with small amount of isopropanol to ~~give~~obtain R-citalopram diol intermediate---L-di-4-methylbenzyl  
10 tartaric acid salt crystal. The obtained salt was then suspended and mixed in toluene, added with NaOH solution and stirred. The solution was placed aside, the organic and inorganic layer was separated. The toluene layer was heated, concentrated under reduced pressure to ~~give~~obtain 14g R-citalopram diol intermediate oil substance (yield: 70%, purity: 99.9%), in which there was 0.4% S-citalopram diol intermediate (chiral HPLC).

15

C. The mother liquor B of Example 2 was concentrated under reduced pressure, 100mL isopropyl ether and NaOH was ~~added, the~~added. The mixture was stirred vigorously and its PH was adjusted to above 10. Then the lower water layer was discarded and the organic layer was dried, concentrated under reduced pressure to eliminate part of isopropyl ether to ~~give~~obtain the solution  
20 of non-racemic S-citalopram diol intermediate mixture that contained lesser R-citalopram diol intermediate, wherein S-enantiomer constituted 76.9%, R-enantiomer constituted 23.1% (chiral HPLC). To the residue solution that still contained some isopropyl ether, 80mL n-heptane was added and stirred, then citalopram diol intermediate was added as crystal seed and crystallization was carried out at 5°C. After 48 hours, the solution was filtrated and the precipitated crystal was  
25 separated from the mother liquor. The mother liquor was evaporated to ~~give~~obtain the oil substance of S-enantiomer ~~alkali~~base, in which S-enantiomer constituted 99.1%, R-enantiomer constituted 0.9% (chiral HPLC). While in the precipitated crystal, S-enantiomer constituted 50.1%, R-enantiomer constituted 49.9% (chiral HPLC).

D. To 50g non-racemic mixture of R-citalopram diol intermediate and S-citalopram diol intermediate, in which R-enantiomer constituted 76.9%, S-enantiomer constituted 23.1%, 120mL 10% ethanol solution was added and the solution was heated, then crystallization was carried out at -5°C. After 48 hours, the solution was filtrated and the precipitated crystal was separated from the mother liquor. The mother liquor was evaporated to ~~give~~obtain the oil substance, in which R-enantiomer constituted 98.8%, S-enantiomer constituted 1.2% (chiral HPLC). While in the precipitated crystal, R-enantiomer constituted 51.3%, S-enantiomer constituted 48.7% (chiral HPLC).

#### Example 3 Preparation of citalopram

To 20g citalopram diol intermediate ~~alkali~~base crystal obtained in Example1, 200ml toluene and 80g phosphoric acid were added, the solution was stirred at 80°C for 2.5 hours and then cooled down to 50°C with ice bath, its PH was adjusted to 10 with 20% NaOH solution. Then toluene solution was separated, washed with water and dried, disposed with silica gel and filtrated, evaporated to eliminate toluene to ~~give~~obtain 17.5g citalopram oil substance. The purity of the product was 99.65% (HPLC, area normalization method), and the yield was over 86%.

#### Example 4 Preparation of citalopram hydrobromic salt

10g citalopram obtained in Example3 was heated and dissolved in 40mL isopropanol. After cooled down, pH of the solution was adjusted to 6-7 with bromic acid. The mixture was disposed with active carbon and filtrated, cooled down and placed aside to crystallize. Then the solution was filtrated and washed to ~~give~~obtain citalopram hydrobromic salt crystal. The obtained salt crystal was recrystallized to ~~give~~obtain 9.82g citalopram hydrobromic salt crystal with the yield of 88.2% and the purity of 99.9% (HPLC, area normalization method).

#### Example 5 Preparation of S-citalopram and its oxalate salt

20g S-citalopram diol intermediate ~~alkali~~base obtained in Example 2 was dissolved in

MARKED-UP SPECIFICATION SHOWING CHANGES MADE

430ml toluene and 23 ml triethylamine was added. The solution was placed in ice bath and stirred, 5.14ml methyl sulfochloride (dissolved in 30ml toluene) was added dropwise. After the reaction was finished, the mixture was washed twice with 0.1M NaOH solution, the organic phase was dried with anhydrous  $K_2CO_3$  and ~~filtrated, the~~filtrated. The filtrate was concentrated to ~~give~~obtain 15.8g S-citalopram oil substance. The obtained S-citalopram oil substance was dissolved in 80 ml acetone and heated, 6.15g oxalic acid was added and dissolved, then the reaction mixture was disposed with active carbon, filtrated, cooled and crystallized. The crystal was filtrated and washed with small amount of acetone to ~~give~~obtain S-citalopram oxalate salt crystal, and the obtained oxalate salt crystal was recrystallized one or more times with acetone.

10 The product, with a yield of 81.8% and a purity of 99.9%(w/w) (HPLC), contained 0.5% R-citalopram oxalate salt (chiral HPLC).

## Abstract

5 The present invention relates to the diol intermediate of citalopram useful for treatment of  
 depression, ~~that~~which ~~is to—say,~~ the crystal of free ~~alkali~~base of  
 3-hydroxymethyl-4-[1-(4-fluorophenyl)-1-hydroxyl-4-(dimethylamino)] butylbenzonitrile and the  
 method of crystallization thereof. The present invention has disclosed the method to prepare pure  
 citalopram and its purified salts through crystallization of the described ~~alkali~~base; ~~the~~ optical  
 10 resolution method of citalopram diol intermediate, the method to prepare S-citalopram and its  
 purified salts by crystals mentioned above. The present invention has also disclosed the method to  
 prepare citalopram and its purified salts, S-citalopram and its purified salts, as well as  
 pharmaceutical formulation thereof obtained. Using methods of the present invention, the quality  
 and yield of the product can be ~~signally~~significantly improved, and the production cost of the  
 medicinal material can be ~~decreased~~reduced.